Overview A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies Status: Completed Trial end date: 2009-11-01 Target enrollment: Participant gender: Summary This study will assess if the combination of sunitinib and pemetrexed is tolerable when coadministered at each recommended dose/schedule. Phase: Phase 1 Details Lead Sponsor: PfizerTreatments: PemetrexedSunitinib